デフォルト表紙
市場調査レポート
商品コード
1344312

網膜用バイオロジクス市場:薬剤クラス別、適応症別、流通チャネル別:世界の機会分析と産業予測、2023-2032年

Retinal Biologics Market By Drug Class, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: | 発行: Allied Market Research | ページ情報: 英文 243 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.54円
網膜用バイオロジクス市場:薬剤クラス別、適応症別、流通チャネル別:世界の機会分析と産業予測、2023-2032年
出版日: 2023年06月01日
発行: Allied Market Research
ページ情報: 英文 243 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

網膜用バイオロジクス市場は2022年に149億米ドルと評価され、2023年から2032年までのCAGRは5.1%で成長し、2032年には247億米ドルに達すると推定されています。

Retinal Biologics Market-IMG1

網膜疾患の治療に使用される生物学的製剤で最も有名なもの1つは、加齢黄斑変性や黄斑浮腫に使用されるラニビズマブ(商品名ルセンティス)です。加齢黄斑変性、糖尿病性網膜症、網膜静脈閉塞症などを対象とするアフリベルセプト(商品名Eylea)もよく使用される生物学的製剤です。ベバシズマブ(商品名アバスチン)は、主にがん治療薬として承認されているが、眼科では同様の適応症で適応外使用されることもあります。

網膜用バイオロジクス市場は、網膜疾患の有病率の上昇、網膜障害疾患に罹患する老年人口の増加、バイオテクノロジーと眼科研究の進歩により大きな成長を遂げています。例えば、(NCBI)によると、2020年には世界中で約1億9,600万人がAMDに罹患し、世界の有病率は8.69%です。また、患者やヘルスケア専門家の間で生物学的製剤の有効性や利点に対する認識が高まっていることも、市場成長の原動力となっています。

さらに、網膜用バイオロジクスの分野で進行中の研究開発が市場成長に寄与しています。製薬会社、学術機関、研究機関は、革新的な治療法の発見と開発、治療効果の向上、利用可能な網膜用バイオロジクスの範囲の拡大に投資しています。例えば、Atsena Therapeutics Inc.は、6~64歳の男性RS1関連X連鎖網膜症(XLRS)を対象に、ATSN-201の安全性と忍容性を評価する臨床試験を実施しています。

さらに、遺伝子工学、組換えDNA技術、標的ドラッグデリバリーシステムなどのバイオテクノロジーの進歩は、網膜用バイオロジクスの分野に革命をもたらし、市場の成長を支えています。これらの進歩により、網膜疾患の根本的なメカニズムに特異的に対処する高度に標的化された有効な治療法の開発が可能になり、治療成績が向上して市場成長が促進されています。しかし、網膜治療薬のコストが高いことが網膜用バイオロジクスの採用を制限し、市場の成長を抑制する可能性があります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
      • 複数の組織による戦略的イニシアチブの増加
      • 網膜疾患の有病率の増加
      • 老年人口の増加
    • 抑制要因
      • 生物学的製剤の高価格
    • 機会
      • 新興市場における成長機会
      • 研究開発活動の活発化
  • COVID-19市場への影響分析

第4章 網膜用バイオロジクス市場:薬剤クラス別

  • 概要
  • VEGF-A拮抗薬
  • その他

第5章 網膜用バイオロジクス市場:適応症別

  • 概要
  • 黄斑変性症
  • 糖尿病網膜症
  • その他

第6章 網膜用バイオロジクス市場:流通チャネル別

  • 概要
  • 病院薬局
  • ドラッグストアおよび小売薬局
  • オンラインプロバイダー

第7章 網膜用バイオロジクス市場:地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ラテンアメリカ
    • 中東・アフリカ

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第9章 企業プロファイル

  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Biogen
  • Novartis AG
  • Coherus BioSciences, Inc.
  • Bayer AG
  • AbbVie Inc.
  • Biocon
  • Outlook Therapeutics, Inc.
  • Amgen Inc.
図表

LIST OF TABLES

  • TABLE 01. GLOBAL RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. RETINAL BIOLOGICS MARKET FOR VEGF-A ANTAGONIST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL VEGF-A ANTAGONIST RETINAL BIOLOGICS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. RETINAL BIOLOGICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 06. RETINAL BIOLOGICS MARKET FOR MACULAR DEGENERATION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. RETINAL BIOLOGICS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. RETINAL BIOLOGICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. RETINAL BIOLOGICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. RETINAL BIOLOGICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. RETINAL BIOLOGICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. RETINAL BIOLOGICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA RETINAL BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 19. U.S. RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE RETINAL BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. UK RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 38. UK RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 39. UK RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 41. ITALY RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 57. CHINA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. INDIA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 60. INDIA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 61. INDIA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA RETINAL BIOLOGICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. LATIN AMERICA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 76. LATIN AMERICA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 77. LATIN AMERICA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. MIDDLE EAST AND AFRICA RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 79. MIDDLE EAST AND AFRICA RETINAL BIOLOGICS MARKET, BY INDICATION, 2022-2032 ($MILLION)
  • TABLE 80. MIDDLE EAST AND AFRICA RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 82. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 83. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 84. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 85. REGENERON PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 86. REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 87. REGENERON PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 88. REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 89. BIOGEN: KEY EXECUTIVES
  • TABLE 90. BIOGEN: COMPANY SNAPSHOT
  • TABLE 91. BIOGEN: PRODUCT SEGMENTS
  • TABLE 92. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 93. BIOGEN: KEY STRATERGIES
  • TABLE 94. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 95. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 96. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 97. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 98. NOVARTIS AG: KEY STRATERGIES
  • TABLE 99. COHERUS BIOSCIENCES, INC.: KEY EXECUTIVES
  • TABLE 100. COHERUS BIOSCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 101. COHERUS BIOSCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 102. COHERUS BIOSCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 103. COHERUS BIOSCIENCES, INC.: KEY STRATERGIES
  • TABLE 104. BAYER AG: KEY EXECUTIVES
  • TABLE 105. BAYER AG: COMPANY SNAPSHOT
  • TABLE 106. BAYER AG: PRODUCT SEGMENTS
  • TABLE 107. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 108. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 109. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 110. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 111. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 112. ABBVIE INC.: KEY STRATERGIES
  • TABLE 113. BIOCON: KEY EXECUTIVES
  • TABLE 114. BIOCON: COMPANY SNAPSHOT
  • TABLE 115. BIOCON: PRODUCT SEGMENTS
  • TABLE 116. BIOCON: PRODUCT PORTFOLIO
  • TABLE 117. OUTLOOK THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 118. OUTLOOK THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 119. OUTLOOK THERAPEUTICS, INC.: PRODUCT SEGMENTS
  • TABLE 120. OUTLOOK THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 121. AMGEN INC.: KEY EXECUTIVES
  • TABLE 122. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 123. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 124. AMGEN INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. RETINAL BIOLOGICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF RETINAL BIOLOGICS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN RETINAL BIOLOGICS MARKET (2023-2032)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALRETINAL BIOLOGICS MARKET
  • FIGURE 09. RETINAL BIOLOGICS MARKET, BY DRUG CLASS, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR VEGF-A ANTAGONIST, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. RETINAL BIOLOGICS MARKET, BY INDICATION, 2022(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR MACULAR DEGENERATION, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF RETINAL BIOLOGICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. RETINAL BIOLOGICS MARKET BY REGION, 2022
  • FIGURE 21. U.S. RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. CANADA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. MEXICO RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. GERMANY RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. FRANCE RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. UK RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. ITALY RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. SPAIN RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. REST OF EUROPE RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. JAPAN RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CHINA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. INDIA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. AUSTRALIA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. SOUTH KOREA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. REST OF ASIA-PACIFIC RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. LATIN AMERICA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. MIDDLE EAST AND AFRICA RETINAL BIOLOGICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 42. COMPETITIVE DASHBOARD
  • FIGURE 43. COMPETITIVE HEATMAP: RETINAL BIOLOGICS MARKET
  • FIGURE 44. TOP PLAYER POSITIONING, 2022
  • FIGURE 45. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 46. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 47. REGENERON PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 52. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 53. COHERUS BIOSCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 58. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. BIOCON: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. BIOCON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 63. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
目次
Product Code: A10946

According to a new report published by Allied Market Research, titled, "Retinal Biologics Market," The retinal biologics market was valued at $14.9 billion in 2022, and is estimated to reach $24.7 billion by 2032, growing at a CAGR of 5.1% from 2023 to 2032.

Retinal Biologics Market - IMG1

One of the most well-known biologics used in the treatment of retinal conditions is Ranibizumab (brand name Lucentis), which is used for age-related macular degeneration and macular edema. Another commonly used biologic is aflibercept (brand name Eylea), which targets AMD age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Bevacizumab (brand name Avastin), although primarily approved for cancer treatment, is sometimes used off-label in ophthalmology for similar indications.

The retina biologics market has experienced significant growth owing to rise in prevalence of retinal diseases, rise in geriatric population suffering from retinal disorders diseases, and advancements in biotechnology and ophthalmic research. For instance, according to the (NCBI) in 2020, approximately 196 million people worldwide to affected by AMD, with a global prevalence of 8.69%. In addition, increase in awareness among patients and healthcare professionals about the efficacy and benefits of biologic therapies drive the market growth.

Furthermore, ongoing research and development activities in the field of retinal biologics contribute to market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available retinal biologics. For instance, Atsena Therapeutics Inc. conducting a clinical trial to evaluate the safety and tolerability of ATSN-201 in male subjects 6 to 64 years old with RS1-associated X-linked retinoschisis (XLRS).

Moreover, advances in biotechnology, such as genetic engineering, recombinant DNA technology, and targeted drug delivery systems, have revolutionized the field of retinal biologics that support the market growth. These advancements have enabled the development of highly targeted and efficacious therapies that specifically address the underlying mechanisms of retinal diseases, improving treatment outcomes and driving the market growth. However, high cost of retinal drugs may limit the adoption of retinal biologic drugs and restrain the market growth.

The retinal biologics market is segmented into drug class, indication, distribution channel, and region. On the basis of drug class, the market is bifurcated into VEGF-A antagonist and others. The VEGF-A antagonist segment is further categorized into Aflibercept, Ranibizumab, and others. On the basis of indication, the market is categorized into macular degeneration, diabetic retinopathy, and others. On the basis of distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. On the basis of, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

Major key players that operate in the retinal biologics market are AbbVie Inc., Amgen Inc., Bayer AG, Biocon, Biogen, Coherus BioSciences, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Outlook Therapeutics, Inc., and Regeneron Pharmaceuticals, Inc. Key players have adopted product launch, product approval, and collaboration as key developmental strategies to improve the product portfolio of the retinal biologics market.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the retinal biologics market analysis from 2022 to 2032 to identify the prevailing retinal biologics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the retinal biologics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global retinal biologics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

By Drug Class

  • VEGF-A Antagonist
    • Type
    • Aflibercept
    • Ranibizumab
    • Others
  • Others

By Indication

  • Macular Degeneration
  • Diabetic Retinopathy
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • AbbVie Inc.
    • Amgen Inc.
    • Bayer AG
    • Biocon
    • Biogen
    • Coherus BioSciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Novartis AG
    • Outlook Therapeutics, Inc.
    • Regeneron Pharmaceuticals, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in strategic Initiatives by several organizations
      • 3.4.1.2. Increase in prevalence of retinal diseases
      • 3.4.1.3. Increase in geriatric population
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of biologic drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
      • 3.4.3.2. Rise in R&D activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: RETINAL BIOLOGICS MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. VEGF-A Antagonist
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. VEGF-A Antagonist Retinal Biologics Market by Type
  • 4.3. Others
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: RETINAL BIOLOGICS MARKET, BY INDICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Macular Degeneration
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Diabetic Retinopathy
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: RETINAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: RETINAL BIOLOGICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Class
    • 7.2.3. Market size and forecast, by Indication
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Class
      • 7.2.5.1.3. Market size and forecast, by Indication
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Class
      • 7.2.5.2.3. Market size and forecast, by Indication
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Class
      • 7.2.5.3.3. Market size and forecast, by Indication
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Class
    • 7.3.3. Market size and forecast, by Indication
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Class
      • 7.3.5.1.3. Market size and forecast, by Indication
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Class
      • 7.3.5.2.3. Market size and forecast, by Indication
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Class
      • 7.3.5.3.3. Market size and forecast, by Indication
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Class
      • 7.3.5.4.3. Market size and forecast, by Indication
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Class
      • 7.3.5.5.3. Market size and forecast, by Indication
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Class
      • 7.3.5.6.3. Market size and forecast, by Indication
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Class
    • 7.4.3. Market size and forecast, by Indication
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Class
      • 7.4.5.1.3. Market size and forecast, by Indication
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Class
      • 7.4.5.2.3. Market size and forecast, by Indication
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Class
      • 7.4.5.3.3. Market size and forecast, by Indication
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Class
      • 7.4.5.4.3. Market size and forecast, by Indication
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Class
      • 7.4.5.5.3. Market size and forecast, by Indication
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Class
      • 7.4.5.6.3. Market size and forecast, by Indication
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Class
    • 7.5.3. Market size and forecast, by Indication
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Class
      • 7.5.5.1.3. Market size and forecast, by Indication
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Middle East And Africa
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Class
      • 7.5.5.2.3. Market size and forecast, by Indication
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. F. Hoffmann-La Roche Ltd.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Regeneron Pharmaceuticals, Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Biogen
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Coherus BioSciences, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Bayer AG
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. AbbVie Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Biocon
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Outlook Therapeutics, Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
  • 9.10. Amgen Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance